Halozyme Therapeutics Inc (NAS:HALO)
$ 59.28 -0.33 (-0.55%) Market Cap: 7.54 Bil Enterprise Value: 8.41 Bil PE Ratio: 19.63 PB Ratio: 16.65 GF Score: 88/100

Q4 2019 Halozyme Therapeutics Inc Earnings Call Transcript

Feb 24, 2020 / 09:30PM GMT
Release Date Price: $21.43 (-1.83%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Halozyme Fourth Quarter 2019 Financial Results Webcast and Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to turn the conference over to Al Kildani, Vice President of Investor Relations and Corporate Communications for Halozyme Therapeutics. Mr. Kildani, please begin.

Albert S. Kildani
Halozyme Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you. Good afternoon, and welcome to our fourth quarter and full year 2019 financial results conference call. In addition to our press release issued today after the close, you can find a supplementary slide presentation that will be referenced during today's call on the Investor Relations section of our website. Leading the call today will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business and review our financial results for the fourth quarter and full year 2019. During

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot